BRAF-targeted therapy and immune responses to melanoma
Shin Foong Ngiow, Deborah A Knight, Antoni Ribas, Grant A McArthur, Mark J Smyth
ONCOIMMUNOLOGY | LANDES BIOSCIENCE | Published : 2013
Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy.
Related Projects (3)
Awarded by National Health and Medical Research Council of Australia (NH&MRC) Program Grant
GAM declares financial research support from Pfizer, Novartis and Millenium. This work was supported by the National Health and Medical Research Council of Australia (NH&MRC) Program Grant (1013667), Project Grant (1002655) and the Victorian Cancer Agency. MJS received support from a NH&MRC Australia Fellowship. SN was supported by a Cancer Research Institute PhD scholarship. GM received support from a NH&MRC Practitioner Fellowship.